Epigenomics to Identify, Analyze Biomarkers for J&J Cancer Program | GenomeWeb
NEW YORK (GenomeWeb News) - Epigenomics will use its differential methylation hybridization chip to help Johnson & Johnson Pharmaceutical Research & Development identify and analyze biomarkers for potential cancer drugs.
 
Terms of the agreement call for Epigenomics to receive an undisclosed upfront payment under the agreement.
 
Additional financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.

Arizona is planning to sue Theranos for "deceptive acts" and misrepresentations of its "capabilities and operation."

If confirmed as Department of Health and Human Services Secretary, Tom Price says he will divest himself of certain holdings, according to Stat News.

Oliver Smithies, who won the Nobel Prize in 2007, has died, the New York Times reports.